Neuroblastoma - Pipeline Review, H2 2017

Date: November 21, 2017
Pages: 506
Price:
US$ 2,000.00
License [?]:
Publisher: Global Markets Direct
Report type: Strategic Report
Delivery: E-mail Delivery (PDF)
ID: N02503ECBC0EN
Leaflet:

Download PDF Leaflet

Neuroblastoma - Pipeline Review, H2 2017
Neuroblastoma - Pipeline Review, H2 2017

SUMMARY

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Neuroblastoma - Pipeline Review, H2 2017, provides an overview of the Neuroblastoma (Oncology) pipeline landscape.

Neuroblastoma is the cancer of the nerve tissues and neural crest cells of adrenal glands, neck, chest or spinal cord, occurring predominantly in children. It usually begins in the adrenal glands further spreading to other parts of the body. The predisposing factors involved in neuroblastoma include genetic conditions. Symptoms include lump in abdomen or chest, weakness, bone pain, breathing problems, dark circles around the eyes and difficulty in movement. The condition may be diagnosed by X-ray imaging, CT scan, MRI, biopsy, urine test, etc. It may be controlled by chemotherapy, radiation therapy, stem cell transplants and medication such as monoclonal antibody regimens.

REPORT HIGHLIGHTS

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Neuroblastoma - Pipeline Review, H2 2017, provides comprehensive information on the therapeutics under development for Neuroblastoma (Oncology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Neuroblastoma (Oncology) pipeline guide also reviews of key players involved in therapeutic development for Neuroblastoma and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies/Universities/Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical, Discovery and Unknown stages are 1, 27, 20, 1, 48, 3 and 1 respectively. Similarly, the Universities portfolio in Phase II, Phase I, Preclinical and Discovery stages comprises 6, 5, 13 and 3 molecules, respectively.

Neuroblastoma (Oncology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

SCOPE
  • The pipeline guide provides a snapshot of the global therapeutic landscape of Neuroblastoma (Oncology).
  • The pipeline guide reviews pipeline therapeutics for Neuroblastoma (Oncology) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Neuroblastoma (Oncology) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Neuroblastoma (Oncology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Neuroblastoma (Oncology)
REASONS TO BUY
  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Neuroblastoma (Oncology).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Neuroblastoma (Oncology) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Introduction
Global Markets Direct Report Coverage
Neuroblastoma - Overview
Neuroblastoma - Therapeutics Development
Pipeline Overview
Pipeline by Companies
Pipeline by Universities/Institutes
Products under Development by Companies
Products under Development by Universities/Institutes
Neuroblastoma - Therapeutics Assessment
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Neuroblastoma - Companies Involved in Therapeutics Development
Ability Pharmaceuticals SL
Actuate Therapeutics Inc
Advanced Accelerator Applications SA
Alissa Pharma
Ampio Pharmaceuticals Inc
APAvadis Biotechnologies Srl
APEIRON Biologics AG
AstraZeneca Plc
Autolus Ltd
Bayer AG
Bellicum Pharmaceuticals Inc
Bexion Pharmaceuticals LLC
BioLineRx Ltd
Biotec Pharmacon ASA
Boehringer Ingelheim GmbH
Bristol-Myers Squibb Co
Cancer Prevention Pharmaceuticals Inc
Cebiotex SL
Celgene Corp
Celldex Therapeutics Inc
Cielo Therapeutics Inc
Cleveland BioLabs Inc
CorMedix Inc
Curis Inc
Cyclacel Pharmaceuticals Inc
DEKK-TEC Inc
EnGeneIC Ltd
Epizyme Inc
Errant Gene Therapeutics LLC
F. Hoffmann-La Roche Ltd
GlaxoSmithKline Plc
Green Cross Cell Corp
Ignyta Inc
Ipsen SA
Juno Therapeutics Inc
Lindis Biotech GmbH
Loxo Oncology Inc
MabVax Therapeutics Holdings Inc
MacroGenics Inc
MediaPharma SRL
Merck & Co Inc
Morphogenesis Inc
Novartis AG
Novogen Ltd
OGD2 Pharma SAS
Pfizer Inc
Phylogica Ltd
Progenics Pharmaceuticals Inc
Recombio SL
Ribomic Inc
Sapience Therapeutics Inc
Sareum Holdings Plc
Sierra Oncology Inc
Sorrento Therapeutics Inc
Syros Pharmaceuticals Inc
Tiltan Pharma Ltd
Neuroblastoma - Drug Profiles
1-B7 - Drug Profile
31-F9 - Drug Profile
9-ING41 - Drug Profile
abexinostat hydrochloride - Drug Profile
ABTL-0812 - Drug Profile
ACY-1035 - Drug Profile
ACY-957 - Drug Profile
afatinib dimaleate - Drug Profile
ALKCAR-15 - Drug Profile
ALKCAR-48 - Drug Profile
ALKCAR-53 - Drug Profile
ALKCAR-58 - Drug Profile
AMB-8LK - Drug Profile
AMXT-1501 + eflornithine hydrochloride - Drug Profile
APN-301 - Drug Profile
AT-69 - Drug Profile
BACPT-DP - Drug Profile
bevacizumab - Drug Profile
BGA-002 - Drug Profile
Bispecific Monoclonal Antibody to Target GD2 and CD3 for Oncology - Drug Profile
BL-8040 - Drug Profile
BPX-701 - Drug Profile
BXQ-350 - Drug Profile
CBL-0137 - Drug Profile
CCT-244747 - Drug Profile
CCT-68127 - Drug Profile
CEB-01 - Drug Profile
Cellular Immunotherapy for GD2 Expressing Solid Tumors - Drug Profile
Cellular Immunotherapy for Neuroblastoma - Drug Profile
Cellular Immunotherapy for Neuroblastoma - Drug Profile
Cellular Immunotherapy for Oncology - Drug Profile
Cellular Immunotherapy to Target CD3 and GD2 for Neuroblastoma - Drug Profile
Cellular Immunotherapy to Target GD2 and CD56 for Solid Tumors - Drug Profile
Cellular Immunotherapy to Target GD2 for Melanoma and Neuroblastoma - Drug Profile
Cellular Immunotherapy to Target GD2 for Neuroblastoma - Drug Profile
Cellular Immunotherapy to Target GD2 for Neuroblastoma - Drug Profile
Cellular Immunotherapy to Target GD2 for Neuroblastoma - Drug Profile
Cellular Immunotherapy to Target GD2 for Neuroblastoma - Drug Profile
Cellular Immunotherapy to Target GD2 for Neuroblastoma - Drug Profile
Cellular Immunotherapy to Target GD2 for Neuroblastoma - Drug Profile
Cellular Immunotherapy to Target GD2 for Neuroblastoma - Drug Profile
Cellular Immunotherapy to Target MAGE-A1, MAGE-A3 and NY-ESO-1 for Oncology - Drug Profile
Celyvir - Drug Profile
ceritinib - Drug Profile
CG-1521 - Drug Profile
CMD-501 - Drug Profile
crizotinib - Drug Profile
CYC-065 - Drug Profile
dactolisib tosylate - Drug Profile
danusertib - Drug Profile
dinutuximab beta - Drug Profile
DS-1647 - Drug Profile
Edotreotide Labeled Yttrium 90 - Drug Profile
eflornithine - Drug Profile
eh-8B6 - Drug Profile
enoblituzumab - Drug Profile
ensartinib - Drug Profile
entrectinib - Drug Profile
fimepinostat - Drug Profile
FSEC - Drug Profile
Gene Therapy to Activate GAS1 for Oncology - Drug Profile
GSK-525762 - Drug Profile
HSV-1716 - Drug Profile
ICA-1 - Drug Profile
Immuncell-LC - Drug Profile
ImmuneFx - Drug Profile
iobenguane sulfate I 131 - Drug Profile
ipilimumab + nivolumab - Drug Profile
irinotecan hydrochloride - Drug Profile
irinotecan hydrochloride + TBio-02 - Drug Profile
JCAR-023 - Drug Profile
Kid EDV - Drug Profile
KOS-1803 - Drug Profile
KTN-0125TEI - Drug Profile
larotrectinib - Drug Profile
lorlatinib - Drug Profile
lutetium Lu 177 dotatate - Drug Profile
M-606 - Drug Profile
M-7085 - Drug Profile
Monoclonal Antibody Conjugate to Target B7-H3 for Oncology - Drug Profile
Monoclonal Antibody Conjugate to Target CD56 for Neuroblastoma - Drug Profile
Monoclonal Antibody Conjugates to Target Glypican-2 for Neuroblastoma - Drug Profile
Monoclonal Antibody to Inhibit GD2 for Oncology - Drug Profile
Monoclonal Antibody to Target Ganglioside GD2 for Neuroblastoma and Osteosarcoma - Drug Profile
MPTEM-1ADC - Drug Profile
NCE-001 - Drug Profile
nifurtimox - Drug Profile
OGD-201 - Drug Profile
olaparib - Drug Profile
Oncolytic Virus for Neuroblastoma - Drug Profile
Oncolytic Virus for Neuroblastoma - Drug Profile
Oncolytic Virus to Activate TIMP3 for Neuroblastoma and Malignant Peripheral Nerve Sheath Tumor - Drug Profile
ORP-008 - Drug Profile
paclitaxel albumin bound - Drug Profile
pazopanib hydrochloride - Drug Profile
pembrolizumab - Drug Profile
Peptides to Inhibit Aminopeptidase A for Endometriosis, Neuroblastoma and Hepatic (Liver) Tumor - Drug Profile
racotumomab - Drug Profile
RBM-001 - Drug Profile
ribociclib succinate - Drug Profile
RNAi Oligonucleotides for Neuroblastoma - Drug Profile
RSF-701 - Drug Profile
SAR-020106 - Drug Profile
SAR-4 - Drug Profile
selumetinib sulfate - Drug Profile
SF-1126 - Drug Profile
SF-2523 - Drug Profile
Small Molecules 3 for Oncology - Drug Profile
Small Molecules to Inhibit ALK for Oncology - Drug Profile
Soluble Beta Glucan - Drug Profile
SRA-737 - Drug Profile
ST-36 - Drug Profile
SY-1365 - Drug Profile
Synthetic Peptide to Inhibit C-Myc for Oncology - Drug Profile
Synthetic Peptide to Inhibit N-Myc for Oncology - Drug Profile
taurolidine - Drug Profile
tazemetostat - Drug Profile
TL-118 - Drug Profile
TR-100 - Drug Profile
TRBS-07 - Drug Profile
Trilexium - Drug Profile
Vaccine for Neuroblastoma - Drug Profile
Vaccine for Neuroblastoma - Drug Profile
Vaccine for Neuroblastoma - Drug Profile
Vaccine to Target GD2 and GD3 for Neuroblastoma - Drug Profile
Vaccine to Target WT1 for Oncology - Drug Profile
vemurafenib - Drug Profile
VIMO-001 - Drug Profile
Neuroblastoma - Dormant Projects
Neuroblastoma - Discontinued Products
Neuroblastoma - Product Development Milestones
Featured News & Press Releases
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

LIST OF TABLES

Number of Products under Development for Neuroblastoma, H2 2017
Number of Products under Development by Companies, H2 2017
Number of Products under Development by Companies, H2 2017 (Contd..1), H2 2017
Number of Products under Development by Companies, H2 2017 (Contd..2), H2 2017
Number of Products under Development by Companies, H2 2017 (Contd..3), H2 2017
Number of Products under Development by Universities/Institutes, H2 2017
Number of Products under Development by Universities/Institutes, H2 2017 (Contd..1), H2 2017
Products under Development by Companies, H2 2017
Products under Development by Companies, H2 2017 (Contd..1), H2 2017
Products under Development by Companies, H2 2017 (Contd..2), H2 2017
Products under Development by Companies, H2 2017 (Contd..3), H2 2017
Products under Development by Companies, H2 2017 (Contd..4), H2 2017
Products under Development by Companies, H2 2017 (Contd..5), H2 2017
Products under Development by Universities/Institutes, H2 2017
Products under Development by Universities/Institutes, H2 2017 (Contd..1), H2 2017
Number of Products by Stage and Target, H2 2017
Number of Products by Stage and Target, H2 2017 (Contd..1), H2 2017
Number of Products by Stage and Target, H2 2017 (Contd..2), H2 2017
Number of Products by Stage and Target, H2 2017 (Contd..3), H2 2017
Number of Products by Stage and Target, H2 2017 (Contd..4), H2 2017
Number of Products by Stage and Mechanism of Action, H2 2017
Number of Products by Stage and Mechanism of Action, H2 2017 (Contd..1), H2 2017
Number of Products by Stage and Mechanism of Action, H2 2017 (Contd..2), H2 2017
Number of Products by Stage and Mechanism of Action, H2 2017 (Contd..3), H2 2017
Number of Products by Stage and Route of Administration, H2 2017
Number of Products by Stage and Molecule Type, H2 2017
Neuroblastoma - Pipeline by Ability Pharmaceuticals SL, H2 2017
Neuroblastoma - Pipeline by Actuate Therapeutics Inc, H2 2017
Neuroblastoma - Pipeline by Advanced Accelerator Applications SA, H2 2017
Neuroblastoma - Pipeline by Alissa Pharma, H2 2017
Neuroblastoma - Pipeline by Ampio Pharmaceuticals Inc, H2 2017
Neuroblastoma - Pipeline by APAvadis Biotechnologies Srl, H2 2017
Neuroblastoma - Pipeline by APEIRON Biologics AG, H2 2017
Neuroblastoma - Pipeline by AstraZeneca Plc, H2 2017
Neuroblastoma - Pipeline by Autolus Ltd, H2 2017
Neuroblastoma - Pipeline by Bayer AG, H2 2017
Neuroblastoma - Pipeline by Bellicum Pharmaceuticals Inc, H2 2017
Neuroblastoma - Pipeline by Bexion Pharmaceuticals LLC, H2 2017
Neuroblastoma - Pipeline by BioLineRx Ltd, H2 2017
Neuroblastoma - Pipeline by Biotec Pharmacon ASA, H2 2017
Neuroblastoma - Pipeline by Boehringer Ingelheim GmbH, H2 2017
Neuroblastoma - Pipeline by Bristol-Myers Squibb Co, H2 2017
Neuroblastoma - Pipeline by Cancer Prevention Pharmaceuticals Inc, H2 2017
Neuroblastoma - Pipeline by Cebiotex SL, H2 2017
Neuroblastoma - Pipeline by Celgene Corp, H2 2017
Neuroblastoma - Pipeline by Celldex Therapeutics Inc, H2 2017
Neuroblastoma - Pipeline by Cielo Therapeutics Inc, H2 2017
Neuroblastoma - Pipeline by Cleveland BioLabs Inc, H2 2017
Neuroblastoma - Pipeline by CorMedix Inc, H2 2017
Neuroblastoma - Pipeline by Curis Inc, H2 2017
Neuroblastoma - Pipeline by Cyclacel Pharmaceuticals Inc, H2 2017
Neuroblastoma - Pipeline by DEKK-TEC Inc, H2 2017
Neuroblastoma - Pipeline by EnGeneIC Ltd, H2 2017
Neuroblastoma - Pipeline by Epizyme Inc, H2 2017
Neuroblastoma - Pipeline by Errant Gene Therapeutics LLC, H2 2017
Neuroblastoma - Pipeline by F. Hoffmann-La Roche Ltd, H2 2017
Neuroblastoma - Pipeline by GlaxoSmithKline Plc, H2 2017
Neuroblastoma - Pipeline by Green Cross Cell Corp, H2 2017
Neuroblastoma - Pipeline by Ignyta Inc, H2 2017
Neuroblastoma - Pipeline by Ipsen SA, H2 2017
Neuroblastoma - Pipeline by Juno Therapeutics Inc, H2 2017
Neuroblastoma - Pipeline by Lindis Biotech GmbH, H2 2017
Neuroblastoma - Pipeline by Loxo Oncology Inc, H2 2017
Neuroblastoma - Pipeline by MabVax Therapeutics Holdings Inc, H2 2017
Neuroblastoma - Pipeline by MacroGenics Inc, H2 2017
Neuroblastoma - Pipeline by MediaPharma SRL, H2 2017
Neuroblastoma - Pipeline by Merck & Co Inc, H2 2017
Neuroblastoma - Pipeline by Morphogenesis Inc, H2 2017
Neuroblastoma - Pipeline by Novartis AG, H2 2017
Neuroblastoma - Pipeline by Novogen Ltd, H2 2017
Neuroblastoma - Pipeline by OGD2 Pharma SAS, H2 2017
Neuroblastoma - Pipeline by Pfizer Inc, H2 2017
Neuroblastoma - Pipeline by Phylogica Ltd, H2 2017
Neuroblastoma - Pipeline by Progenics Pharmaceuticals Inc, H2 2017
Neuroblastoma - Pipeline by Recombio SL, H2 2017
Neuroblastoma - Pipeline by Ribomic Inc, H2 2017
Neuroblastoma - Pipeline by Sapience Therapeutics Inc, H2 2017
Neuroblastoma - Pipeline by Sareum Holdings Plc, H2 2017
Neuroblastoma - Pipeline by Sierra Oncology Inc, H2 2017
Neuroblastoma - Pipeline by Sorrento Therapeutics Inc, H2 2017
Neuroblastoma - Pipeline by Syros Pharmaceuticals Inc, H2 2017
Neuroblastoma - Pipeline by Tiltan Pharma Ltd, H2 2017
Neuroblastoma - Dormant Projects, H2 2017
Neuroblastoma - Dormant Projects, H2 2017 (Contd..1), H2 2017
Neuroblastoma - Dormant Projects, H2 2017 (Contd..2), H2 2017
Neuroblastoma - Discontinued Products, H2 2017

LIST OF FIGURES

Number of Products under Development for Neuroblastoma, H2 2017
Number of Products under Development by Companies, H2 2017
Number of Products under Development by Universities/Institutes, H2 2017
Number of Products by Top 10 Targets, H2 2017
Number of Products by Stage and Top 10 Targets, H2 2017
Number of Products by Top 10 Mechanism of Actions, H2 2017
Number of Products by Stage and Top 10 Mechanism of Actions, H2 2017
Number of Products by Routes of Administration, H2 2017
Number of Products by Stage and Routes of Administration, H2 2017
Number of Products by Top 10 Molecule Types, H2 2017
Number of Products by Stage and Top 10 Molecule Types, H2 2017

COMPANIES MENTIONED

Ability Pharmaceuticals SL
Actuate Therapeutics Inc
Advanced Accelerator Applications SA
Alissa Pharma
Ampio Pharmaceuticals Inc
APAvadis Biotechnologies Srl
APEIRON Biologics AG
AstraZeneca Plc
Autolus Ltd
Bayer AG
Bellicum Pharmaceuticals Inc
Bexion Pharmaceuticals LLC
BioLineRx Ltd
Biotec Pharmacon ASA
Boehringer Ingelheim GmbH
Bristol-Myers Squibb Co
Cancer Prevention Pharmaceuticals Inc
Cebiotex SL
Celgene Corp
Celldex Therapeutics Inc
Cielo Therapeutics Inc
Cleveland BioLabs Inc
CorMedix Inc
Curis Inc
Cyclacel Pharmaceuticals Inc
DEKK-TEC Inc
EnGeneIC Ltd
Epizyme Inc
Errant Gene Therapeutics LLC
F. Hoffmann-La Roche Ltd
GlaxoSmithKline Plc
Green Cross Cell Corp
Ignyta Inc
Ipsen SA
Juno Therapeutics Inc
Lindis Biotech GmbH
Loxo Oncology Inc
MabVax Therapeutics Holdings Inc
MacroGenics Inc
MediaPharma SRL
Merck & Co Inc
Morphogenesis Inc
Novartis AG
Novogen Ltd
OGD2 Pharma SAS
Pfizer Inc
Phylogica Ltd
Progenics Pharmaceuticals Inc
Recombio SL
Ribomic Inc
Sapience Therapeutics Inc
Sareum Holdings Plc
Sierra Oncology Inc
Sorrento Therapeutics Inc
Syros Pharmaceuticals Inc
Tiltan Pharma Ltd
Skip to top


Neuroblastoma - Pipeline Review, H1 2017 US$ 2,000.00 Jun, 2017 · 417 pages
Sutro Biopharma, Inc. - Product Pipeline Review - 2016 US$ 1,500.00 Feb, 2016 · 34 pages
Fibrosarcoma - Pipeline Review, H2 2017 US$ 2,000.00 Aug, 2017 · 83 pages
Malignant Pleural Mesothelioma - Pipeline Review, H1 2016 US$ 2,000.00 May, 2016 · 319 pages

Ask Your Question

Neuroblastoma - Pipeline Review, H2 2017
Company name*:
Contact person*:
Phone/fax*:
Email*:
Request invoice
Your enquiry:
Please click on a Check Box below to confirm you are not a robot: